Home- Workshops & Training
- Conferences
- Program
- Location
- Sponsors & Exhibitors
- Call for Contributions
- Bursary Awards
- Poster Session
- Program 2007
- Program 2006
- Open Event
- Knowledge Management
- Decision Support
- Metabolomics
- Banik, G
- Beger, R
- Berger, A
- Connor, S
- Fiehn, O
- Garrett, T
- Harrigan, G
- Lane, A
- Kristall, B
- Maguire, G
- Nemec, E
- Robertson, D
- Young, S
- Biomarkers
- Predictive Toxicology
- Medicinal Chemistry
- Screening
- Drug Design
- Photo Gallery
- Program
- Exhibition
- Registration
- About
- Overview
- Contact
- Support
- Schedule
|
|
|
|
|
|
|
|
|
Richard D. Beger, (Ph.D.) is currently Branch Chief, Center for Metabolomics, in the Division of Systems Toxicology at the FDA’s National Center for Toxicological Research in Jefferson, Arkansas. He received his Ph.D. theoretical biophysics from Purdue University in 1991. He performed a two year postdoctoral fellowship at Johns Hopkins Medical School, Department of Biophysics and Biophysical Chemistry in Baltimore, MD and a 5 year postdoctoral position at Wesleyan University, Department of Chemistry in Middletown, CT. He has been at the National Center for Toxicological Research (NCTR), US FDA, in Jefferson, AR for the last eight years. He is an adjunct Associate Professor in Department of Biochemistry and Molecular Biology at the University of Arkansas for Medical Sciences. He is an active member of the Society of Toxicology since 2004 and on the technical advisory board for the Metabolomics Society. He is involved with the Metabolomics Society quest for developing Metabolomics reporting standards.
|
|
FDA’s Critical Path Initiative: Opportunities for Metabolomics
Richard D. Beger, FDA
Richard D. Beger, Branch Chief, Center for Metabolomics, Division of Systems Toxicology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR 72079-9502, USA
Critical Path is the FDA's initiative to identify the most pressing developmental problems with medical products and the opportunities for rapid improvement in terms of public health benefit. The primary purpose of the initiative is to ensure that basic scientific discoveries translate into new and better medical treatments. On March 16, 2006, the FDA released a Critical Path Opportunities Report. The report listed 76 Critical Path Opportunities that can be found at http://www.fda.gov/oc/initiatives/criticalpath. The list contains many opportunities in new ‘omic’ technologies including metabolomics. Metabolomics can play a role in a number of these opportunities including better evaluation tools and models for diseases, better identification and quantification of safety biomarkers, and improving the measurement of patient response. The voluntary submission of genomics data (VGDS) to the FDA is now accepting proteomics and metabolomics data sets. Discussion on how the VGDS operates and what its goals are will be discussed. A general overview of the research strategies, goals and results of the Center for Metabolomics will be discussed.
|
|
|
|
|
|
|
|
|
|
|
